SCHEMBL29805013

SCHEMBL29805013

COc1cc(-c2ncc(C)cn2)cc2cncnc12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 1/20 0.40
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
KDR P35968 1/20 0.37
JAK3 P52333 1/20 0.37
AURKB Q96GD4 1/20 0.37
EGFR P00533 2/20 0.36
PDGFRB P09619 4/20 0.35
PDGFRA P16234 4/20 0.35
CRHR1 P34998 1/20 0.34
MAPT P10636 1/20 0.34
BRD9 Q9H8M2 1/20 0.33
BRD7 Q9NPI1 1/20 0.33
S1PR1 P21453 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14595283 0.81 EGFR (0.41) FGFR4JAK2JAK1TYK2KDR
SCHEMBL22745001 0.78 PIK3CA (0.42)
SCHEMBL19878485 0.78 PDGFRB (0.50) FGFR4JAK2JAK1TYK2KDR
SCHEMBL19878211 0.78 PDGFRB (0.52) FGFR4JAK2JAK1TYK2KDR
SCHEMBL29804594 0.76 FGFR4 (0.38) FGFR4JAK2JAK1TYK2KDR
SCHEMBL22714767 0.75 SMPD3 (0.35) JAK2JAK1TYK2KDRJAK3
SCHEMBL29676533 0.75 ALDH1A1 (0.42) MAPTALDH1A1
SCHEMBL22714759 0.75 ALDH1A1 (0.42) MAPTALDH1A1
SCHEMBL29804794 0.75 PDGFRB (0.52) FGFR4JAK2JAK1TYK2KDR
Hydrochloric Acid SCHEMBL28859453 0.74 PDGFRB (0.51) FGFR4JAK2JAK1TYK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US disclosed
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER LABORATORIES, INC. 2022-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 FGFR4 1926/4885JAK2 2512/4885JAK1 2909/4885
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX5, P2RX1 FGFR4 1926/4885JAK2 2512/4885JAK1 2909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.